Voluntary Faculty
Voluntary faculty are typically clinicians or others who are employed outside of the School but make significant contributions to department programs at the medical center or at affiliate institutions.
Voluntary rank detailsHe (Howard) Zhang
Assistant Clinical ProfessorAbout
Research
Publications
2026
Clinical application of deep learning-based measurement of glomerular morphometry in IgAN
Xu L, Zhang X, Dong Z, Chen P, Jiang L, Liu L, Zhou X, Lv J, Xiao L, Shi S, Zhang H. Clinical application of deep learning-based measurement of glomerular morphometry in IgAN. Frontiers In Immunology 2026, 17: 1910367. PMID: 42614397, PMCID: PMC13481774, DOI: 10.3389/fimmu.2026.1910367.Peer-Reviewed Original ResearchGlucocorticoid-Modulated Molecular Signatures and Prediction of Treatment Efficacy in IgA Nephropathy.
Wang L, He Y, Tian W, Wang J, Shi S, Liu L, Monaghan H, Wong M, Lv J, Chen Y, Zhang Y, Zhang H. Glucocorticoid-Modulated Molecular Signatures and Prediction of Treatment Efficacy in IgA Nephropathy. Journal Of The American Society Of Nephrology 2026 PMID: 42536435, DOI: 10.1681/asn.0000001208.Peer-Reviewed Original ResearchEfficacy and safety of sibeprenlimab in IgA nephropathy: interim analysis of the China cohort in the phase 3 VISIONARY trial
Zhang H, Liew A, Wong M, Xie D, Wang C, Lu W, Li G, Xia J, Fajardo C, Hafkin J, Lv J. Efficacy and safety of sibeprenlimab in IgA nephropathy: interim analysis of the China cohort in the phase 3 VISIONARY trial. Clinical Kidney Journal 2026, 19: sfag222. PMID: 42633049, PMCID: PMC13498869, DOI: 10.1093/ckj/sfag222.Peer-Reviewed Original ResearchBeyond galactose deficiency: redefining pathogenic IgA in IgA nephropathy
Zhang Y, Barratt J, Zhao M, Zhang H, Lv J. Beyond galactose deficiency: redefining pathogenic IgA in IgA nephropathy. Kidney International 2026, 110: 541-545. PMID: 42412024, DOI: 10.1016/j.kint.2026.05.014.Peer-Reviewed Original ResearchTime-Updated Hematuria and Kidney Disease Progression in IgAN
Tang C, Si F, Chen P, Hou W, Yang H, Lv J, Shi S, Zhou X, Liu L, Zhang H. Time-Updated Hematuria and Kidney Disease Progression in IgAN. Kidney International Reports 2026, 11: 106653. PMID: 42471814, PMCID: PMC13380167, DOI: 10.1016/j.ekir.2026.106653.Peer-Reviewed Original ResearchCirculating Antinephrin Antibodies in Adult Chinese Patients With IgAN and Nephrotic-Range Proteinuria
Si F, Shu Y, Tang C, Huang J, Chen P, Lv J, Zhu L, Shi S, Zhou X, Zhang H, Zhao M, Cui Z, Liu L. Circulating Antinephrin Antibodies in Adult Chinese Patients With IgAN and Nephrotic-Range Proteinuria. Kidney International Reports 2026, 11: 106640. PMID: 42404869, PMCID: PMC13329496, DOI: 10.1016/j.ekir.2026.106640.Peer-Reviewed Original ResearchHematuria Remission and Prognosis in IgA Nephropathy: A Post Hoc Analysis of the TESTING Randomized Clinical Trial
Wu J, Kim D, Guo L, Wang J, Yang H, Chen P, Li J, Monaghan H, Wong M, Perkovic V, Lv J, Zhang H. Hematuria Remission and Prognosis in IgA Nephropathy: A Post Hoc Analysis of the TESTING Randomized Clinical Trial. American Journal Of Kidney Diseases 2026, 88: 278-281. PMID: 42214605, DOI: 10.1053/j.ajkd.2026.02.649.Peer-Reviewed Original ResearchTherapeutic efficacy and antigenicity of a novel PEGylated IgA protease in preclinical models of IgA nephropathy
Shen X, Shu C, Dong Y, Li J, Li R, Zan J, Xie X, Jin J, Zhang H, Lv J. Therapeutic efficacy and antigenicity of a novel PEGylated IgA protease in preclinical models of IgA nephropathy. Kidney International 2026, 110: 463-476. PMID: 42176777, DOI: 10.1016/j.kint.2026.04.020.Peer-Reviewed Original ResearchTelitacicept for IgA Nephropathy — Interim Analysis of a Phase 3 Trial
Lv J, Liu L, Wang W, Wang X, Zuraw Q, Perkovic V, Fang J, Zhang H. Telitacicept for IgA Nephropathy — Interim Analysis of a Phase 3 Trial. The New England Journal Of Medicine 2026, 394: 1916-1924. PMID: 42127391, DOI: 10.1056/nejmoa2514415.Peer-Reviewed Original ResearchAdultB-Cell Activating FactorCreatinineDisease ProgressionDouble-Blind MethodFemaleGlomerular Filtration RateGlomerulonephritis, IGAHumansInjections, SubcutaneousMaleMiddle AgedProteinuriaRecombinant Fusion ProteinsSignal TransductionTreatment OutcomeTumor Necrosis Factor Ligand Superfamily Member 13Asian expert consensus on high-quality hypertension management
Liu J, Kario K, Ding X, Li Z, Gao T, Li Y, Zhang Y, Chen W, Chia Y, Fan Y, Hoshide S, Mao H, Shin J, Sukonthasarn A, Teo B, Turana Y, Yao L, Zhang H, Wang J. Asian expert consensus on high-quality hypertension management. Hypertension Research 2026, 49: 2141-2155. PMID: 42120775, PMCID: PMC13333500, DOI: 10.1038/s41440-026-02644-2.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus Statements